Abstract
ObjectivesTo understand stakeholders’ perceptions of the access barriers to quality-assured diagnostics and medicines for leishmaniasis in the high-burden region of eastern Africa, and to identify key bottlenecks to improve the supply of commodities for neglected tropical diseases.DesignDesk reviews and qualitative in-depth interview study with purposive sampling.MethodsA landscape analysis through literature and desk review was performed. Next, 29 representatives from international organisations, non-governmental agencies, national control programmes from six countries (Ethiopia, Kenya, Somalia, South Sudan, Sudan and Uganda) and manufacturers were interviewed between May and July 2018. Participants were selected purposively and expanded through a snowballing technique.Data analysis was aided by NVivo, applying the framework method as a part of the thematic content analysis approach.ResultsThe barriers along the visceral leishmaniasis (VL) supply chain were identified as emerging themes, grouped across supply chain activities and health systems component(s). Stakeholders expressed the perception of progress, but bottlenecks persist. VL medicines, in general, lack multisource production capacity and with small market volume, expansion of suppliers is difficult. Procurement is plagued by forecasting difficulties, complex regulatory policies and procedures, and distribution challenges. Weak communication and coordination across different levels resulted in shortages and loss of trust among different actors. Cross-cutting issues spanned from limited political and resource commitment due to low awareness and limited in-country capacity. However, study respondents were optimistic to pursue several remedies, most importantly to build bridges between supply and demand sides through continued dialogue and collaborations. Diagnostics supply has mostly been overlooked; thus, improved investment in this area is needed.ConclusionsAddressing supply barriers in eastern Africa requires consistent, specific efforts at the global and national levels, progressing from current partnerships and agreements. Priority actions include pooled procurement, improved forecast, and increased commitment and resources. Sustainability remains an elusive goal, yet to be integrated into discussions moving forward.
Funder
H2020 Marie Skłodowska-Curie Actions
Reference62 articles.
1. Drug development for neglected diseases: a deficient market and a public-health policy failure
2. The drug and vaccine landscape for neglected diseases (2000-11): a systematic assessment;Pedrique;Lancet Glob Health,2013
3. Access to Essential Drugs in Poor CountriesA Lost Battle?
4. Global leishmaniasis surveillance update, 1998-2016;World Health Organisation;Wkly Epidemiol Rec,2018
5. Leishmaniasis in high-burden countries: an epidemiological update based on data reported in 2014;WHO;Wkly Epidemiol Rec,2016
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献